MarkHerz inks MoU with Technical University of Munich Hospital to develop cardiovascular and diabetes-targeted AAV gene therapies: Munich Thursday, June 5, 2025, 15:00 Hrs [IST] M ...

AI is revolutionizing the pharma supply chain by automating manual tasks, monitoring risks and providing predictive insights.

The MAHA war on expertise leaves Americans ever more vulnerable to predators and scams, which in turn exacerbates a much ...

Moleculin Biotech has announced encouraging topline efficacy outcomes from its US Phase IB/II trial, MB-107, of Annamycin.